Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia

Leukemia

Volumn 17, Issue 1, 2003, Pages 138-148

  Bjorklund E ^a   Mazur, J ^a,b   Soderhall S ^a   Porwit MacDonald, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b INSTITUTE OF MOTHER AND CHILD   (Poland)

Author keywords

Acute lymphoblastic leukemia; Disease free survival; Flow cytometry; Immunophenotyping; Minimal residual disease

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; B LYMPHOCYTE ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; FOLINIC ACID; GLYCOPHORIN A; MERCAPTOPURINE; METHOTREXATE; MICROSOMAL AMINOPEPTIDASE; PREDNISOLONE; T LYMPHOCYTE ANTIGEN; UNINDEXED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BONE MARROW; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0037265763     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402736     Document Type: Article

References (48)

1. Pui CH, Boyett JM, Rivera GK, Hancock ML, Sandlund JT, Ribeiro RC, Rubnitz JE, Behm FG, Raimondi SC, Gajjar A, Razzouk B, Campana D, Kun LE, Relling MV, Evans WE. Long-term results of total therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14: 2286-2294.
2. Eden OB, Harrison G, Richards S, Lilleyman JS, Bailey CC, Chessells JM, Hann IM, Hill FG, Gibson BE. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia 2000; 14: 2307-2320.
3. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G, Mellander L, Makipernaa A, Nygaard R, Saarinen-Pihkala UM. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000; 14: 2267-2275.
4. Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave H, Thyss A, Benoit Y, Dastugue N, Fournier M, Souillet G, Manel AM, Robert A, Nelken B, Millot F, Lutz P, Rialland X, Mechinaud F, Boutard P, Behar C, Chantraine JM, Plouvier E, Laureys G, Brock P, Uyttebroeck A, Margueritte G, Plantaz D, Norton L, Francotte N, Gyselinck J, Waterkeyn C, Solbu G, Philippe N, Otten J. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia 2000; 14: 2257-2266.
5. Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G, Janka-Schaub GE, Kamps W, Masera G, Sallan S, Tsuchida M, Vilmer E. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 2193-2194.
6. Mathe G, Weiner R, Pouillart P, Schwarzenberg L, Jasmin C, Schneider M, Hayat M, Amiel JL, de Vassal F, Rosenfeld C. BCG in cancer immunotherapy: experimental and clinical trials of its use in treatment of leukemia minimal and or residual disease. Natl Cancer Inst Monogr 1973; 39: 165-175.
7. Gutterman JU, Mavligit G, Burgess MA, McCredie KB, Hunter C, Freireich EJ, Hersh EM. Immunodiagnosis of acute leukemia: detection of residual disease. J Natl Cancer Inst 1974; 53: 389-392.
8. Bradstock KF, Janossy G, Tidman N, Papageorgiou ES, Prentice HG, Willoughby M, Hoffbrand AV. Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. Leuk Res 1981; 5: 301-309.
9. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416-1434.
10. San Miguel JF, Ciudad J, Vicriales MB, Orfao A, Lucio P, Porwit-MacDonald A, Gaipa G, van Wering E, van Dongen JJ. Immunophenotypical detection of minimal residual disease in acute leukemia. Crit Rev Oncol Hematol 1999; 32: 175-185.
11. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409-417.
12. Pui CH, Evans WE. Genetic abnormalities and drug resistance in acute lymphoblastic leukemia. Adv Exp Med Biol 1999; 457: 383-389.
13. Forestier E, Johansson B, Borgstrom G, Kerndrup G, Johansson J, Heim S. Cytogenetic findings in a population-based series of 787 childhood acute lymphoblastic leukemias from the Nordic countries. The NOPHO Leukemia Cytogenetic Study Group. Eur J Haematol 2000; 64: 194-200.
14. Biondi A, Valsecchi MG, Seriu T, D'Aniello E, Willemse MJ, Fasching K, Parmunzio A, Gadner H, Schrappe M, Kamps WA, Bartram CR, van Dongen JJ, Panzer-Grumayer ER. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 2000; 14: 1939-1943.
15. Cave H, Guidal C, Rohrlich P, Delfau MH, Broyart A, Lescoeur B, Rahimy C, Fenneteau O, Monplaisir N, d'Auriol L. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood 1994; 83: 1892-1902.
16. Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA, van Wering ER, van Dongen JJ, van der Schoot CE. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2000; 14: 1426-1435.
17. Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N, Fritsch G, Gadner H. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952-1958.
18. Campana D, Neale CA, Coustan-Smith E, Pui CH. Detection of minimal residual disease in acute lymphoblastic leukemia: the St Jude experience. Leukemia 2001; 15: 278-279.
19. Ciudad J, San Miguel JF, Lopez-Berges MC, Vidriales B, Valverde B, Ocqueteau M, Mateos G, Caballero MD, Hernandez J, Moro MJ, Mateos MV, Orfao A. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998; 16: 3774-3781.
20. Philippe J, Louagie H, Thierens H, Vral A, Cornelissen M, De Ridder L. Quantification of apoptosis in lymphocyte subsets and effect of apoptosis on apparent expression of membrane antigens. Cytometry 1997; 29: 242-249.
21. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738.
22. Cave H, van der Werff ten Bosch, Suciu S, Guical C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591-598.
23. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, Sandlund JT, Rivera GK, Rubnitz JE, Ribeiro RC, Pui CH, Campana D. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696.
24. Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen N, Wesenberg F, Jonsson OG, Forestier E, Schmiegelow K. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002; 99: 1253-1258.
25. Szczepanski T, Flohr T, van der Velden VH, Bartram CR, van Dongen JJ. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002; 15: 37-57.
26. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997; 336s: 317-323.
27. Farahat N, Lens D, Zomas A, Morilla R, Matutes E, Catovsky D. Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursors. Br J Haematol 1995; 91: 640-646.
28. Dworzak MN, Fritsch C, Fleischer C, Printz D, Froschl G, Buchinger P, Mann G, Cadner H. Comparative phenotype mapping of normal vs malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations. Exp Hematol 1998; 26: 305-313.
29. Ciudad J, Orfao A, Vidriales B, Macedo A, Martinez A, Gonzalez M, Lopez-Berges MC, Valverde B, San Miguel JF. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection. Haematologica 1998; 83: 1069-1075.
30. Lucio P, Parreira A, van den Beemd MW, van Lochem FG, van Wering ER, Baars E, Porwit-MacDonald A, Bjorklund E, Gaipa G, Biondi A, Orfao A, Janossy G, van Dongen JJ, San Miguel JF. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia 1999; 13: 419-427.
31. Weir EG, Cowan K, LeBeau P, Borowitz MJ. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 1999; 13: 558-567.
32. Porwit-MacDonald A, Bjorklund E, Lucio P, van Lochem EG, Mazur J, Parreira A, van den Beemd MW, van Wering ER, Baars E, Gaipa G, Biondi A, Ciudad J, van Dongen JJ, San Miguel JF, Orfao A. BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000; 14: 816-825.
33. McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001 15: 2498-2507.
34. Campana D. Applications of cytometry to study acute leukemia: in vitro determination of drug sensitivity and detection of minimal residual disease. Cytometry 1994; 18: 68-74.
35. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, Rubnitz JE, Rivera GK, Sandlund JT, Pui CH, Campana D. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550-554.
36. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Calton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-458.
37. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
38. Gustafsson G, Kreuger A, Clausen N, Garwicz S, Kristinsson J, Lie SO, Moe PJ, Perkkio M, Yssing M, Saarinen-Pihkala UM. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Acta Paediatr 1998; 87: 1151-1161.
39. Lucio P, Caipa G, van Lochem EG, van Wering ER, Porwit-MacDonald A, Faria T, Bjorklund E, Biondi A, van den Beemd MW, Baars E, Vidriales B, Parreira A, van Dongen JJ, San Miguel JF, Orfao A. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. Leukemia 2001; 15: 1185-1192.
40. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139-152.
41. Malec M, Bjorklund E, Soderhall S, Mazur J, Sjogren AM, Pisa P, Bjorkholm M, Porwit-MacDonald A. Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL. Leukemia 2001; 15: 716-727.
42. Neale GA, Coustan-Smith E, Pan Q, Chen X, Gruhn B, Stow P, Behm FG, Pui CH, Campana D. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 1999; 13: 1221-1226.
43. van Wering ER, Beishuizen A, Roeffen ET, van der Linden-Schrever BE, Verhoeven MA, Hahlen K, Hooijkaas H, van Dongen JJ. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia 1995; 9: 1523-1533.
44. Macedo A, San Miguel JF, Vidriales MB, Lopez-Berges MC, Garcia-Marcos MA, Gonzalez M, Landolfi C, Orfao A. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol 1996; 49: 15-18.
45. Ciudad J, San Miguel JF, Lopez-Berges MC, Garcia MM, Gonzalez M, Vazquez L, del Canizo MC, Lopez A, van Dongen JJ, Orfao A. Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL. Br J Haematol 1999; 104: 695-705.
46. Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 783-785.
47. Foroni L, Coyle LA, Papaioannou M, Yaxley JC, Sinclair MF, Chim JS, Cannell P, Secker-Walker LM, Mehta AB, Prentice HG, Hoffbrand AV. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response. Leukemia 1997; 11: 1732-1741.
48. de Haas V, Verhagen OJ, von dem B, Kroes W, van den Berg H, van der Schoot CE. Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy. Leukemia 2001; 15: 134-140.